GlassScriptPhysician profile
Carson Craig Doty
NPI 1215543467
$6,120.15
in general payments reported to CMS, 2019-2025
30 companies · $907 in 2025
The $907 reported for 2025 was more than what 82% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,247 · 2022: $971 · 2023: $1,091 · 2024: $903 · 2025: $907.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,811 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,811.34 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $1,395.25 | 2021 | |
| Abbvie INC. | $982.22 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $651.85 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $472.62 | 2021-2025 | |
| Glaxosmithkline, LLC. | $317.26 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Otsuka America Pharmaceutical, INC. | $316.34 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $303.40 | 2021-2025 | Jardiance |
| Lilly USA, LLC | $226.47 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $218.98 | 2023-2025 | Otezla, Repatha, Krystexxa |
| Novo Nordisk INC | $202.41 | 2021-2024 | Rybelsus, Ozempic, Tresiba |
| Exact Sciences Corporation | $194.85 | 2024-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $145.03 | 2022-2025 | Xifaxan |
| Amarin Pharma, INC. | $142.93 | 2021 | |
| Astellas Pharma US INC | $107.41 | 2024 | Veozah |
| Organon LLC | $57.60 | 2023 | Nexplanon |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $52.46 | 2021-2022 | |
| Edwards Lifesciences Corporation | $47.04 | 2022-2025 | Sapien 3 Ultra Resilia |
| Janssen Pharmaceuticals, INC | $35.35 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.19 | 2023 | Trintellix |
| Dexcom, INC. | $31.17 | 2023 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $25.00 | 2022 | |
| Abbott Laboratories | $23.47 | 2024 | Freestyle Libre 3 |
| Vbi Vaccine (Delaware) INC. | $22.36 | 2022 | |
| Tolmar, INC. | $20.02 | 2023 | |
| Averitas Pharma INC. | $19.36 | 2024 | Qutenza |
| Supernus Pharmaceuticals, INC. | $19.09 | 2025 | Qelbree |
| Pfizer INC. | $16.94 | 2022 | |
| Ethicon US, LLC | $15.03 | 2021 | |
| Esperion Therapeutics, INC. | $14.35 | 2021 | |
| Currax Pharmaceuticals LLC | $12.70 | 2023 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carson Doty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.